Core Insights - Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for liver and viral diseases [4] Group 1: Upcoming Events - Aligos management will present at the Jefferies London Healthcare Conference on November 17, 2025, at 3:00 PM GMT [2] - Aligos will also participate in the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, at 2:00 PM ET [3] - Presentations will be accessible via the "Investors" page on Aligos' website, with a replay available for at least 30 days [3] Group 2: Company Overview - Aligos Therapeutics aims to improve patient outcomes through best-in-class therapies targeting high unmet medical needs, including chronic hepatitis B virus (HBV) infection, obesity, and metabolic dysfunction-associated steatohepatitis (MASH) [4] - The company utilizes a science-driven approach and deep R&D expertise to advance its therapeutic pipeline [4]

Core Viewpoint - Aligos Therapeutics, Inc. is set to report its third quarter 2025 financial results on November 6, 2025, before the U.S. financial markets open [1] Company Overview - Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing best-in-class therapies for liver and viral diseases [2] - The company aims to improve patient outcomes through a science-driven approach and deep R&D expertise [2] - Aligos has a pipeline targeting high unmet medical needs, including chronic hepatitis B virus (HBV) infection, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses [2]

Core Insights - Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for liver and viral diseases [3] - The company will present at the H.C. Wainwright Liver Disease Conference on October 21-22, 2025 [1] - A webcast of the presentation will be available on Aligos' website, with a replay accessible for at least 30 days [2] Company Overview - Aligos Therapeutics aims to improve patient outcomes through best-in-class therapies targeting high unmet medical needs, including chronic hepatitis B virus (HBV) infection and metabolic dysfunction-associated steatohepatitis (MASH) [3] - The company utilizes a science-driven approach and extensive R&D expertise to advance its therapeutic pipeline [3]

Core Insights - Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for liver and viral diseases [3] Group 1: Company Overview - Aligos Therapeutics aims to improve patient outcomes through best-in-class therapies targeting high unmet medical needs such as chronic hepatitis B virus (HBV) infection and metabolic dysfunction-associated steatohepatitis (MASH) [3] - The company will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025 [1] Group 2: Presentation Details - A webcast of the presentation will be available on Aligos' website, with a replay accessible for at least 30 days following the event [2]

Core Viewpoint - Aligos Therapeutics, Inc. is set to report its second quarter 2025 financial results on August 6, 2025, after the U.S. financial markets close [1] Company Overview - Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing best-in-class therapies for liver and viral diseases [2] - The company aims to improve patient outcomes through a science-driven approach and deep R&D expertise [2] - Aligos has a purpose-built pipeline targeting high unmet medical needs, including chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses [2]

Core Points - Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for liver and viral diseases [3] - The company will present at the Jefferies Global Healthcare Conference on June 5, 2025 [1] - A live webcast of the presentation will be available on Aligos' website, with a replay accessible for at least 30 days [2] Company Overview - Aligos Therapeutics aims to improve patient outcomes through best-in-class therapies targeting high unmet medical needs such as chronic hepatitis B virus infection and metabolic dysfunction-associated steatohepatitis (MASH) [3] - The company utilizes a science-driven approach and has deep R&D expertise to advance its therapeutic pipeline [3]